Investigational drug · Phase 2
SCG101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma Recurrent.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SCG101"
First trial start
2022
Oct 26, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCG101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatitis B Virus Related Hepatocellular Carcinoma
- Hepatocellular Carcinoma Recurrent
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Hepatitis B · Oncology · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "SCG101" as an intervention, largest first.
SCG Cell Therapy Pte. Ltd.Industry
NCT05417932 · 46 participants (planned) · Start Oct 26, 2022 · Primary completion Sep 2025
Drug: SCG101 · For: Hepatitis B Virus Related Hepatocellular Carcinoma; Hepatocellular Carcinoma Recurrent
Sites: New York, New York; Hong Kong, Hong Kong; Singapore, Singapore · 6 sites in all
- A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-RelatedStatus unknown
SCG Cell Therapy Pte. Ltd.Industry
NCT06617000 · 38 participants (planned) · Start Oct 25, 2022 · Primary completion Dec 31, 2025
Drug: SCG101 · For: HCC; Hepatitis B Virus Related Hepatocellular Carcinoma; Hepatocellular Carcinoma
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 7 sites in all
- Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCCStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT05339321 · 36 participants (planned) · Start Apr 14, 2021 · Primary completion Jul 2023
Drug: PD1/PD-L1 checkpoint inhibitor · For: Hepatocellular Carcinoma
Sites: Beijing, China; Shanghai, China; Shenyang, China · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.
Wu X, Quan D, Li W, et al. · Gut 2025
- Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting.
Wan X, Wisskirchen K, Jin T, et al. · Clin Mol Hepatol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.